Drug Profile
Presatovir - Gilead Sciences
Alternative Names: GS-5806Latest Information Update: 24 Sep 2020
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Class Amines; Antivirals; Chlorinated hydrocarbons; Piperidines; Pyrazoles; Pyrimidines; Pyrrolidines; Small molecules; Sulfonamides
- Mechanism of Action Viral fusion protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 24 Sep 2020 No development reported - Phase-II for Respiratory syncytial virus infections (In the elderly, In adults) in Taiwan, Brazil, Spain, Sweden, Switzerland, Singapore, Germany, Poland, Netherlands, South Korea, Italy, Israel, Belgium, USA, France, New Zealand, Australia, United Kingdom, Canada (PO) (Gilead Sciences website, September 2020)
- 18 May 2018 Safety and efficacy data from a phase IIb trial in Respiratory syncytial virus infections presented at the 114th International Conference of the American Thoracic Society (AST-2018)
- 27 Sep 2017 Gilead Sciences completes a phase II trial for Respiratory syncytial virus infections (In adults, In the elderly) in USA, Belgium, Canada, Australia, France, Germany, Netherlands and United Kingdom (PO) (NCT02534350)